MCM 998
Alternative Names: BCMA-targeted chimeric antigen receptor T-cell therapy - Novartis; CD19-targeted chimeric antigen receptor T-cell therapy - Novartis; LXG-250; MCM-998Latest Information Update: 14 Mar 2022
At a glance
- Originator Novartis
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 24 Feb 2022 MCM 998 is available for licensing as of 09 Feb 2022. https://www.novartis.com/partnering
- 09 Feb 2022 Phase-I clinical trials in Cancer in Switzerland (Parenteral) (Novartis pipeline, February 2022)